Sign In
Buy BCYC
$4.11
-0.0600 (-1.44%)
At Close: Aug 10, 2026
OXURION to Participate in Upcoming Investor Meetings
01:30am, Wednesday, 31'st Mar 2021
Leuven, BE, Boston, MA, US – March 31st, 2021 – 07.30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies,
Bicycle Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
07:00am, Thursday, 11'th Mar 2021
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl
OXURION to Participate in Upcoming Investor Meetings
02:00am, Monday, 08'th Mar 2021
Leuven, BE, Boston, MA, US – March 8, 2021 – 08.00 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard-of-care ophthalmic therapies, wi
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycli
Bicycle Therapeutics Announces Pipeline Progress Update
07:00am, Thursday, 14'th Jan 2021
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicycl
Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.
04:05pm, Friday, 20'th Nov 2020
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its prop
The Global E-Bike Market will grow by 8118.92 K units during 2020-2024
Investors Who Bought Bicycle Therapeutics (NASDAQ:BCYC) Shares A Year Ago Are Now Up 122%
12:03pm, Thursday, 06'th Aug 2020
Unless you borrow money to invest, the potential losses are limited. But if you pick the right business to buy shares...
Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference
08:05pm, Wednesday, 05'th Aug 2020
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today annou
Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
10:59am, Wednesday, 05'th Aug 2020
Bicycle Therapeutics plc (NASDAQ:BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycles®) technology, today repor
Bicycle Therapeutics (BCYC) Catches Eye: Stock Jumps 8.9%
12:37pm, Wednesday, 24'th Jun 2020
Bicycle Therapeutics (BCYC) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Bicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board
10:59am, Tuesday, 23'rd Jun 2020
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today annou
Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today annou
Is Bicycle Therapeutics Stock a Buy?
11:56am, Saturday, 13'th Jun 2020
In 2018, the founder of Bicycle Therapeutics (NASDAQ: BCYC), Sir Gregory Winter, was awarded the Nobel Prize in chemistry for his work in developing phage display (use of viruses that infect bacteria
